- Home
- Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from HFA 2024
Advancing Patient Care in Hypertrophic Cardiomyopathy: Key Insights from HFA 2024
- Guidelines
- Heart Failure
Available Credit:
- 0.50
Course Published On:
Course Expiry Date:
![](https://assets.radcliffemedicaleducation.org/s3fs-public/styles/course_banner/public/course/2024-06/DELV-19340_CYTO_HFA24_RME_1920x580%20%281%29.jpg?itok=9r1j_kvB)
Overview
This course which was recorded at HFA 2024 sees Dr Caroline Coats, Glasgow University, UK, and Dr Ahmad Masri, Oregon Health and Science University, US, discussing and exploring the pivotal advancements in managing hypertrophic cardiomyopathy unveiled at the conference.
This programme is thoughtfully divided into four chapters, facilitating a smooth journey through the latest HCM trial data, including a comprehensive analysis of the SEQUOIA trial results; the dynamic evolution of HCM management with forthcoming updates to practice guidelines and expert strategies for seamlessly integrating these evidence-based innovations into clinical practice.
Join Dr Coats and Dr Masri as they navigate the forefront of HCM management, offering invaluable insights and actionable strategies to elevate patient care.
Support Statement
This programme is supported by an unrestricted educational grant by Cytokinetics.
Joint Accreditation and Credit Designation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of i3 Health and Radcliffe Medical Education. In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
i3 Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instruction to Participants
There is no fee for taking part in this online learning activity. Activities are designed to be completed within 75 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the course outline information supplied and complete pre-test questions prior to starting the activity.
- Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Disclaimer
The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labelling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
i3 Health and Radcliffe Medical Education planners, reviewers, and managers have nothing to disclosure.
i3 Health and Radcliffe have mitigated all relevant financial relationships.
Dr Masri discloses he has served as a consultant for: Cytokinetics, BMS, Eidos/BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Prothena, BioMarin, AstraZeneca, and Tenaya.
Dr Coats discloses she has served as an advisory board or panel for: Cytokinetics, Roche Diagnostics
Technical/Credit Queries
Technical queries about this activity should be directed to info@radcliffe-group.com. Questions regarding activity credit should be directed to support@i3Health.com.
Target Audience
- Cardiologists
- Heart Failure Specialty Physicians
- Associated Nurses
- Nurse Practitioners
- Trainees
Learning Objectives
Upon completion of this activity, participants will be able to:
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice
Module |
Title |
Duration |
Speakers |
---|---|---|---|
Part 1 | Emerging Data from HFA 2024: SEQUOIA-HCM | 10m 50s | Ahmad Masri Caroline Coats |
Part 2 | Emerging Data from HFA 2024: Posters and Abstracts | 2m 16s | Ahmad Masri Caroline Coats |
Part 3 | Guidelines Updates | 7m 21s | Ahmad Masri Caroline Coats |
Part 4 | Translation to Clinical Practice | 9m 44s | Ahmad Masri Caroline Coats |
Emerging Data from HFA 2024: Posters and Abstracts
Duration: 2m 16s
Speakers: Ahmad Masri Caroline Coats
Course Director
Speaker
0.5 AMA PRA Category 1 Credit™